Harmony Biosciences Hldg Inc (HRMY) valuation
Harmony Biosciences Hldg P/E ratio history
Harmony Biosciences Hldg trades at 12.6 times its earnings over the last twelve months and 6.3 times the earnings analysts expect over the next twelve. At its last 5 fiscal year ends its P/E ranged from 13.7 (year to Dec 2024) to 73.5 (year to Dec 2021), with a median of 15.2.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $37.42 | $2.71 | 13.8 | 9.9 |
| Dec 31, 2024 | $34.41 | $2.51 | 13.7 | 11.6 |
| Dec 31, 2023 | $32.30 | $2.13 | 15.2 | 10.4 |
| Dec 31, 2022 | $55.10 | $2.97 | 18.6 | — |
| Dec 31, 2021 | $42.64 | $0.58 | 73.5 | 18.1 |
| Dec 31, 2020 | $36.15 | -$2.48 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Harmony Biosciences Hldg valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Harmony Biosciences HldgHRMY | $2.24B | 12.6 | 6.3 | 2.3 |
| NeogenomicsNEO | $2.23B | — | 58.8 | 2.8 |
| Vera TherapeuticsVERA | $2.22B | — | — | — |
| XencorXNCR | $2.21B | — | — | 21.1 |
| Transmedics GroupTMDX | $2.28B | 17.1 | 35.1 | 3.4 |
| ProgynyPGNY | $2.29B | 31.7 | 13.3 | 1.7 |
| Ufp TechnologiesUFPT | $2.20B | 30.7 | 25.3 | 3.5 |
| Arcus BiosciencesRCUS | $2.29B | — | — | 19.6 |
| BiohavenBHVN | $2.32B | — | — | — |
| Peer median | 30.7 | 30.2 | 3.4 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: HRMY financials · HRMY returns
No forecast, no recommendation. This page describes Harmony Biosciences Hldg Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.